Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis

• Published in: Journal of the Pakistan Medical Association 2024-06, Vol.74 (6 (Supple-6)), p.S34-S40
• Main Authors: Harsoyo, Primasitha Maharani, Hermawan, Hanestya Oky, Hariftyani, Arisvia Sukma, Shabrina, Farah Aisha, Paramitha, Anisya Dinda, Desita, Saskia Ratna, Oktaviono, Yudi Her
• Format: Article
• Language: English
• Subjects: Angiogenesis; Diabetes Mellitus, Type 2 - drug therapy; E-Selectin - blood; Humans; Hypoglycemic Agents - therapeutic use; Intercellular Adhesion Molecule-1 - blood; Intercellular Adhesion Molecule-1 - metabolism; Metformin - therapeutic use; Plasminogen Activator Inhibitor 1 - blood; Plasminogen Activator Inhibitor 1 - metabolism; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1 - blood; Vascular Endothelial Growth Factor A - blood; Vascular Endothelial Growth Factor A - metabolism; von Willebrand Factor - metabolism
• ISSN: 0030-9982; 0030-9982
• DOI: 10.47391/JPMA.S6-ACSA-07

To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients. The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4. Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p